Omega-6 & Breast Cancer: Study Links Fat to Aggressive Growth
- New research indicates that linoleic acid, a common omega-6 fatty acid, substantially enhances the growth of triple-negative breast cancer, a especially challenging subtype to treat.
- The study, published in Science, reveals that linoleic acid activates a major growth pathway in tumor cells by binding to a protein known as FABP5.
- John Blenis, a professor of cancer research at Weill Cornell Medicine and senior author of the study, said the discovery clarifies the connection between dietary fats and cancer.
Omega-6 fatty acids, specifically linoleic acid, are now directly linked to enhanced growth in aggressive triple-negative breast cancer, a major finding from Weill Cornell Medicine. This groundbreaking study reveals how the primarykeyword affects tumor progress by activating a key growth pathway through the secondarykeyword protein, FABP5.Discover how your diet, specifically your intake of seed oils and animal products, could be impacting your risk. The research clarifies the critical link between dietary fats and cancer,which will help guide personalized nutritional advice. News Directory 3 is following this story closely, bringing you the latest developments. These findings may lead to tailored interventions for patients. Discover what’s next regarding potential therapies.
Linoleic Acid Fuels Growth of Aggressive Breast Cancer
Updated June 17, 2025
New research indicates that linoleic acid, a common omega-6 fatty acid, substantially enhances the growth of triple-negative breast cancer, a especially challenging subtype to treat. The study, conducted by Weill Cornell Medicine investigators, suggests that dietary intake of this fatty acid, found in soybean and safflower oils, as well as animal products like pork and eggs, could play a critical role in tumor growth.
The study, published in Science, reveals that linoleic acid activates a major growth pathway in tumor cells by binding to a protein known as FABP5. This activation is especially pronounced in triple-negative breast cancer cells, where FABP5 is abundant. Experiments using mouse models confirmed that a diet high in linoleic acid accelerated tumor growth.
Dr. John Blenis, a professor of cancer research at Weill Cornell Medicine and senior author of the study, said the discovery clarifies the connection between dietary fats and cancer. It also helps define which patients might benefit most from tailored nutritional advice.
Linoleic acid is considered an essential nutrient, supporting various bodily functions. However, its increased presence in Western diets, due to the widespread use of seed oils in processed foods, has raised concerns about its potential link to rising rates of diseases, including breast cancer.Previous studies have yielded inconclusive results regarding this connection.
The researchers focused on breast cancer and the ability of omega-6 fatty acids, particularly linoleic acid, to stimulate the mTORC1 pathway, a nutrient-sensing growth regulator. They found that linoleic acid indeed activates mTORC1 in triple-negative breast cancer cells and animal models. This subtype-specific effect occurs because the fatty acid forms a complex with FABP5, leading to mTORC1 activation and subsequent cancer cell growth.
Further analysis of patients with newly diagnosed triple-negative breast cancer revealed elevated levels of FABP5 and linoleic acid in their tumors and blood samples.
The findings highlight the notable role of linoleic acid in breast cancer development, particularly in the context of triple-negative tumors. The study also establishes a specific mechanism through which this dietary component influences the disease.
The identification of FABP5 as a key player suggests its potential as a biomarker for personalized nutritional and therapeutic interventions for patients with triple-negative breast cancer, which currently lacks targeted therapies.
While the research primarily focused on breast cancer, initial investigations suggest that the omega-6-FABP5-mTORC1 pathway may also promote the growth of certain prostate cancer subtypes.
“There may be a broader role for FABP5-mTORC1 signaling in other cancer types and even in common chronic diseases such as obesity and diabetes,” said Dr. Nikos koundouros, a postdoctoral research associate in the Blenis laboratory.
What’s next
Future research will explore the broader implications of the FABP5-mTORC1 signaling pathway in other cancers and chronic conditions, potentially leading to new strategies for prevention and treatment.
- Once-Weekly Workout May Help Reduce Belly Fat: New Study
- Rare Celestial Events in August: Perseid Meteor Showers and Total Solar Eclipse
- KAIST Researchers Develop New Treatment for Cancer Cachexia (newsy-today.com)
- Argentina’s Economy 2026-2036: A 10-Year Growth Forecast Under Javier Milei (archynewsy.com)